Disruption of the Fibroinflammatory Loop: A Therapeutic Strategy for Cardiac Fibrosis in Non-Ischemic Cardiomyopathy

Read full text Summarise with VIRAT
Authors: Hongyu Qiu, Inna P. Gladysheva
Cited by: 0
References: 47

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

In non-ischemic cardiomyopathy, inflammation is closely associated with cardiac fibrosis, which significantly contributes to adverse outcomes and promotes heart failure (HF). Recent mechanistic studies have demonstrated that interactions between fibrotic and inflammatory pathways create a dynamic, self-perpetuating fibroinflammatory loop, thereby accelerating disease progression. New mono or combination therapies that target this cycle by blocking specific inflammatory signals, modulating the immune response, and altering extracellular matrix (ECM) stiffness may halt or even reverse fibrosis. This opinion article discusses critical recent discoveries, current obstacles, and future opportunities in developing inflammation-focused treatments for cardiac fibrosis in non-ischemic cardiomyopathies.

Fields of Study & Subjects

Cardiac Fibrosis and Remodeling Congenital heart defects research Cardiomyopathy and Myosin Studies

Publication details

Journal / source
Reviews in Cardiovascular Medicine
Volume
27
Issue
3
Pages
48589–48589
Publication date
16 March 2026
Language
EN